ECCMID
Copenhagen | April 2023
- All-cause and attributable mortality in invasive candidiasis and/or candidaemia with rezafungin and caspofungin treatment: outcomes from the ReSTORE trial [Presentation] [04732]
- Safety outcomes with rezafungin and caspofungin in the treatment of candidaemia and/or invasive candidiasis: Phase 3 data from the ReSTORE trial [P2061] [04525]
- Rezafungin Activity against Candida and Aspergillus Isolates Causing Invasive Infections in European Medical Centres (2019–2021) [P508] [00508]
- Rezafungin Activity against Candidemia isolates collected from European medical centres (2019–2021) [P509] [00509]
- Rezafungin and caspofungin treatment response in candidaemia/invasive candidiasis by baseline Candidaspecies: Analysis of pooled Phase 2 and Phase 3 results [P2048] [04353]
- Treatment outcomes in candidaemia and/or invasive candidiasis among patients receiving rezafungin or caspofungin while the fungal culture was still positive [P2063] [04913]
- Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with candidaemia and/or invasive candidiasis: Integrated analysis of pooled Phase 2 and Phase 3 data [03861] [ePoster]
- First case of Candida glabrata prosthetic knee infection treated with rezafungin: case report [P3398]
|
ECCMID
Lisbon – Virtual Hybrid | April 2022
|
EBMT
Virtual | March 2022
|
ISICEM
Virtual | August 2021
|
ISHAM-Asia
Virtual | August 2021
|
ICHS SYMPOSIUM
VIRTUAL | February 2021
|
SCCM
VIRTUAL | January 2021
|
ACCP
VIRTUAL | October 2020
|